CIBRN Poll #4: Biosimilars have been available and used in other jurisdictions around the world. How long after a biosimilar has been introduced and used by patients in a real-world setting would you feel comfortable with its potential efficacy and safety?

If you haven’t yet participated in the poll, we invite you to share your views. Click here to answer.

Biosimilars have been available and used in other jurisdictions around the world. How long after a biosimilar has been introduced and used by patients in a real-world setting would you feel comfortable with its potential efficacy and safety?

  • Right away
  • A few months
  • 1 year
  • 2 years
  • 3 years
  • 5 years
  • Never

Click here to answer

CIBRN Poll #3: The introduction and promotion of biosimilar medications is fueled by a need to lower the overall cost of healthcare delivery. Where do you think we should be looking for cost savings?

If you haven’t yet participated in the poll, we invite you to share your views. Click here to answer.

The introduction and promotion of biosimilar medications is fueled by a need to lower the overall cost of healthcare delivery. Where do you think we should be looking for cost savings? Select one or more.

  • Hospitals
  • Physicians
  • Prescription Drugs
  • Long-term Care
  • Community Care
  • Other

Click here to answer

CIBRN Poll #2: With the expanding number of options available for treating specific conditions, is there merit in limiting choice by using a stratified or step approach to selection?

If you haven’t yet participated in the poll, we invite you to share your views:

With the expanding number of options available for treating specific conditions, is there merit in limiting choice by using a stratified or step approach to selection?

  • Yes, stratification should be used with the more costly biologic therapies.
  • Yes, stratification should be used for all classical and biologic therapies.
  • No, physicians and patients should be free to select any biologic therapy after failing traditional classical therapies.
  • No, physicians and patients should be free to select any classical or biologic therapy in any order once systemic therapy is indicated.

Click here to answer

Now Available Online: Archived recording of CIBRN Webinar #2 of 2019, originally hosted live on June 19, 2019

We invite you to view the archived recording of CIBRN Webinar #2 of 2019, which was hosted live by the CIBRN Leaders on June 19, 2019.

We invite you to view the archived recording of CIBRN Webinar #2 of 2019, which was hosted live by the CIBRN Leaders on June 19, 2019. Click to view the video: http://bit.ly/2FZ7crQ

The webinar will review the the following discussions in the CIBRN community:

  • CIBRN 2019 Q3: Are you aware of Health Canada’s new policy on the naming of biologic reference drugs and their biosimilars? Do you think it is sufficient to prevent confusion between drugs and to allow for proper pharmacovigilance? [View 2 replies to date]
  • CIBRN 2019 Q4: Aside from any scientific concerns, do you feel prepared to handle conversations with patients around transitioning (non-medical switching) of stable patients on reference biologics to biosimilars? Do you have the resources available to manage this situation? If not, what resources would you require? [View 2 replies to date]

Click to view the video: http://bit.ly/2FZ7crQ

Now Available Online: Archived recording of CIBRN Webinar #1 of 2019, originally hosted live on May 22, 2019

We invite you to view the archived recording of CIBRN Webinar #1 of 2019 which was hosted live by the CIBRN Leaders on May 22, 2019. Click to view the video: http://bit.ly/2WJLldN

The webinar reviews the following discussions and podcast in the CIBRN community:

  • CIBRN 2019 Q1: Should drug approvals be based on efficacy and demonstrated need, or should pharmacoeconomics be a larger consideration? [View 5 replies to date]
  • CIBRN 2019 Q2: Should manufacturers’ rebates be kept confidential, or should full transparency be expected, in order to more properly compare costs between originators and biosimilars? [View 4 replies to date]
  • CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18) [Listen to the podcast]

Click to view the video: http://bit.ly/2WJLldN